Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 517162, 7 pages
http://dx.doi.org/10.1155/2008/517162
Review Article

Potential Therapeutic Targets for PPAR 𝜸 after Spinal Cord Injury

Department of Neuroscience and Center for Brain and Spinal Cord Repair, The Ohio State University, Columbus, OH 43210, USA

Received 3 December 2007; Accepted 7 January 2008

Academic Editor: Paul Drew

Copyright © 2008 Dana M. McTigue. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. K. Hihi, L. Michalik, and W. Wahli, “PPARs: transcriptional effectors of fatty acids and their derivatives,” Cellular and Molecular Life Sciences, vol. 59, no. 5, 790 pages, 2002. View at Publisher · View at Google Scholar
  2. C. Blanquart, O. Barbier, J. C. Fruchart, B. Staels, and C. Glineur, “Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation,” Journal of Steroid Biochemistry and Molecular Biology, vol. 85, no. 2–5, 267 pages, 2003. View at Publisher · View at Google Scholar
  3. R. Bordet, T. Ouk, O. Petrault et al., “PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases,” Biochemical Society Transactions, vol. 34, no. 6, 1341 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  4. M. Lehrke and M. A. Lazar, “The many faces of PPARγ,” Cell, vol. 123, no. 6, 993 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  5. N. A. Victor, E. W. Wanderi, J. Gamboa et al., “Altered PPARγ expression and activation after transient focal ischemia in rats,” European Journal of Neuroscience, vol. 24, no. 6, 1653 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  6. Z. Ou, X. Zhao, L. A. Labiche et al., “Neuronal expression of peroxisome proliferator-activated receptor-γ (PPARγ) and 15d-prostaglandin J2-mediated protection of brain after experimental cerebral ischemia in rat,” Brain Research, vol. 1096, no. 1, 196 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  7. G. E. Landreth and M. T. Heneka, “Anti-inflammatory actions of peroxisome proliferator-activated receptor γ agonists in Alzheimer's disease,” Neurobiology of Aging, vol. 22, no. 6, 937 pages, 2001. View at Publisher · View at Google Scholar
  8. R. Genolet, W. Wahli, and L. Michalik, “PPARs as drug targets to modulate inflammatory responses?,” Current Drug Targets—Inflammation & Allergy, vol. 3, no. 4, 361 pages, 2004. View at Publisher · View at Google Scholar
  9. A. Bernardo and L. Minghetti, “PPAR-γ agonists as regulators of microglial activation and brain inflammation,” Current Pharmaceutical Design, vol. 12, no. 1, 93 pages, 2006. View at Publisher · View at Google Scholar
  10. L. H. Sekhon and M. G. Fehlings, “Epidemiology, demographics, and pathophysiology of acute spinal cord injury,” Spine, vol. 26, 2 pages, 2001. View at Publisher · View at Google Scholar
  11. K. D. Anderson, “Targeting recovery: priorities of the spinal cord-injured population,” Journal of Neurotrauma, vol. 21, no. 10, 1371 pages, 2004. View at Publisher · View at Google Scholar
  12. R. P. Bunge, W. R. Puckett, J. L. Becerra, A. Marcillo, and R. M. Quencer, “Observations on the pathology of human spinal cord injury. A review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination,” Advances in Neurology, vol. 59, 75 pages, 1993. View at Google Scholar
  13. B. A. Kakulas, “A review of the neuropathology of human spinal cord injury with emphasis on special features,” Journal of Spinal Cord Medicine, vol. 22, no. 2, 119 pages, 1999. View at Google Scholar
  14. C. Profyris, S. S. Cheema, D. Zang, M. F. Azari, K. Boyle, and S. Petratos, “Degenerative and regenerative mechanisms governing spinal cord injury,” Neurobiology of Disease, vol. 15, no. 3, 415 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  15. D. M. McTigue, R. Tripathi, P. Wei, and A. T. Lash, “The PPAR γ agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury,” Experimental Neurology, vol. 205, no. 2, 396 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. S.-W. Park, J.-H. Yi, G. Miranpuri et al., “Thiazolidinedione class of peroxisome proliferator-activated receptor γ agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 3, 1002 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  17. D. J. McAdoo, G.-Y. Xu, G. Robak, and M. G. Hughes, “Changes in amino acid concentrations over time and space around an impact injury and their diffusion through the rat spinal cord,” Experimental Neurology, vol. 159, no. 2, 538 pages, 1999. View at Publisher · View at Google Scholar · View at PubMed
  18. G.-Y. Xu, M. G. Hughes, L. Zhang, L. Cain, and D. J. McAdoo, “Administration of glutamate into the spinal cord at extracellular concentrations reached post-injury causes functional impairments,” Neuroscience Letters, vol. 384, no. 3, 271 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  19. L. J. Rosenberg, Y. D. Teng, and J. R. Wrathall, “2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline reduces glial loss and acute white matter pathology after experimental spinal cord contusion,” Journal of Neuroscience, vol. 19, no. 1, 464 pages, 1999. View at Google Scholar
  20. J. R. Wrathall, Y. D. Teng, and R. Marriott, “Delayed antagonism of AMPA/kainate receptors reduces long-term functional deficits resulting from spinal cord trauma,” Experimental Neurology, vol. 145, no. 2, 565 pages, 1997. View at Publisher · View at Google Scholar · View at PubMed
  21. C. Romera, O. Hurtado, J. Mallolas et al., “Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARγ target gene involved in neuroprotection,” Journal of Cerebral Blood Flow and Metabolism, vol. 27, no. 7, 1327 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  22. X. Zhao, Z. Ou, J. C. Grotta, N. Waxham, and J. Aronowski, “Peroxisome-proliferator-activated receptor-γ (PPARγ) activation protects neurons from NMDA excitotoxicity,” Brain Research, vol. 1073-1074, no. 1, 460 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  23. E. D. Hall and J. E. Springer, “Neuroprotection and acute spinal cord injury: a reappraisal,” NeuroRX, vol. 1, no. 1, 80 pages, 2004. View at Publisher · View at Google Scholar
  24. J. E. Springer, R. D. Azbill, R. J. Mark, J. G. Begley, G. Waeg, and M. P. Mattson, “4-hydroxynonenal, a lipid peroxidation product, rapidly accumulates following traumatic spinal cord injury and inhibits glutamate uptake,” Journal of Neurochemistry, vol. 68, no. 6, 2469 pages, 1997. View at Publisher · View at Google Scholar
  25. R. D. Azbill, X. Mu, A. J. Bruce-Keller, M. P. Mattson, and J. E. Springer, “Impaired mitochondrial function, oxidative stress and altered antioxidant enzyme activities following traumatic spinal cord injury,” Brain Research, vol. 765, no. 2, 283 pages, 1997. View at Publisher · View at Google Scholar
  26. J. Luo, K. Uchida, and R. Shi, “Accumulation of acrolein-protein adducts after traumatic spinal cord injury,” Neurochemical Research, vol. 30, no. 3, 291 pages, 2005. View at Publisher · View at Google Scholar
  27. Y. Xiong, A. G. Rabchevsky, and E. D. Hall, “Role of peroxynitrite in secondary oxidative damage after spinal cord injury,” Journal of Neurochemistry, vol. 100, no. 3, 639 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  28. W. Xu, L. Chi, R. Xu et al., “Increased production of reactive oxygen species contributes to motor neuron death in a compression mouse model of spinal cord injury,” Spinal Cord, vol. 43, no. 4, 204 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  29. P. G. Sullivan, S. Krishnamurthy, S. P. Patel, J. D. Pandya, and A. G. Rabchevsky, “Temporal characterization of mitochondrial bioenergetics after spinal cord injury,” Journal of Neurotrauma, vol. 24, no. 6, 991 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  30. J. M. Wingrave, K. E. Schaecher, E. A. Sribnick et al., “Early induction of secondary injury factors causing activation of calpain and mitochondria-mediated neuronal apoptosis following spinal cord injury in rats,” Journal of Neuroscience Research, vol. 73, no. 1, 95 pages, 2003. View at Publisher · View at Google Scholar · View at PubMed
  31. J. Culman, Y. Zhao, P. Gohlke, and T. Herdegen, “PPAR-γ: therapeutic target for ischemic stroke,” Trends in Pharmacological Sciences, vol. 28, no. 5, 244 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  32. B. Schütz, J. Reimann, L. Dumitrescu-Ozimek et al., “The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice,” Journal of Neuroscience, vol. 25, no. 34, 7805 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  33. D. L. Feinstein, E. Galea, V. Gavrilyuk et al., “Peroxisome proliferator-activated receptor-γ agonists prevent experimental autoimmune encephalomyelitis,” Annals of Neurology, vol. 51, no. 6, 694 pages, 2002. View at Publisher · View at Google Scholar · View at PubMed
  34. M. T. Heneka, T. Klockgether, and D. L. Feinstein, “Peroxisome proliferator-activated receptor-γ ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo,” Journal of Neuroscience, vol. 20, no. 18, 6862 pages, 2000. View at Google Scholar
  35. Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman, “Activation of cerebral peroxisome proliferator-activated receptors γ promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats,” FASEB Journal, vol. 20, no. 8, 1162 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  36. M. T. Heneka, D. L. Feinstein, E. Galea, M. Gleichmann, U. Wüllner, and T. Klockgether, “Peroxisome proliferator-activated receptor γ agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase,” Journal of Neuroimmunology, vol. 100, no. 1-2, 156 pages, 1999. View at Publisher · View at Google Scholar
  37. M. P. Pereira, O. Hurtado, A. Cárdenas et al., “The nonthiazolidinedione PPARγ agonist L-796,449 is neuroprotective in experimental stroke,” Journal of Neuropathology and Experimental Neurology, vol. 64, no. 9, 797 pages, 2005. View at Google Scholar
  38. X. Zhao, Y. Zhang, R. Strong, J. C. Grotta, and J. Aronowski, “15d-prostaglandin J2 activates peroxisome proliferator-activated receptor-γ, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats,” Journal of Cerebral Blood Flow & Metabolism, vol. 26, no. 6, 811 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. A. Bernardo, G. Levi, and L. Minghetti, “Role of the peroxisome proliferator-activated receptor-γ (PPAR-γ) and its natural ligand 15-deoxy-Δ12,14-prostaglandin J2 in the regulation of microglial functions,” European Journal of Neuroscience, vol. 12, no. 7, 2215 pages, 2000. View at Publisher · View at Google Scholar
  40. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, 79 pages, 1998. View at Publisher · View at Google Scholar · View at PubMed
  41. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, 82 pages, 1998. View at Publisher · View at Google Scholar · View at PubMed
  42. T. V. Petrova, K. T. Akama, and L. J. Van Eldik, “Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Δ12,14-prostaglandin J2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 8, 4668 pages, 1999. View at Publisher · View at Google Scholar
  43. T. Dehmer, M. T. Heneka, M. Sastre, J. Dichgans, and J. B. Schulz, “Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation,” Journal of Neurochemistry, vol. 88, no. 2, 494 pages, 2004. View at Google Scholar
  44. M. Niino, K. Iwabuchi, S. Kikuchi et al., “Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-γ,” Journal of Neuroimmunology, vol. 116, no. 1, 40 pages, 2001. View at Publisher · View at Google Scholar
  45. C. K. Combs, D. E. Johnson, J. C. Karlo, S. B. Cannady, and G. E. Landreth, “Inflammatory mechanisms in Alzheimer's disease: inhibition of β- amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists,” Journal of Neuroscience, vol. 20, no. 2, 558 pages, 2000. View at Google Scholar
  46. T. Breidert, J. Callebert, M. T. Heneka, G. Landreth, J. M. Launay, and E. C. Hirsch, “Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease,” Journal of Neurochemistry, vol. 82, no. 3, 615 pages, 2002. View at Publisher · View at Google Scholar
  47. G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, 25573 pages, 1998. View at Publisher · View at Google Scholar
  48. A. Diab, C. Deng, J. D. Smith et al., “Peroxisome proliferator-activated receptor-γ agonist 15-deoxy-Δ12,14-prostaglandin J2 ameliorates experimental autoimmune encephalomyelitis,” Journal of Immunology, vol. 168, no. 5, 2508 pages, 2002. View at Google Scholar
  49. P. G. Popovich, Z. Guan, P. Wei, I. Huitinga, N. van Rooijen, and B. T. Stokes, “Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury,” Experimental Neurology, vol. 158, no. 2, 351 pages, 1999. View at Publisher · View at Google Scholar · View at PubMed
  50. J. R. Bethea, H. Nagashima, M. C. Acosta et al., “Systemically administered interleukin-10 reduces tumor necrosis factor-α production and significantly improves functional recovery following traumatic spinal cord injury in rats,” Journal of Neurotrauma, vol. 16, no. 10, 851 pages, 1999. View at Google Scholar
  51. D. P. Stirling, K. Khodarahmi, J. Liu et al., “Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury,” Journal of Neuroscience, vol. 24, no. 9, 2182 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  52. D. Gris, D. R. Marsh, M. A. Oatway et al., “Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function,” Journal of Neuroscience, vol. 24, no. 16, 4043 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  53. S. M. Lee, T. Y. Yune, S. J. Kim et al., “Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat,” Journal of Neurotrauma, vol. 20, no. 10, 1017 pages, 2003. View at Publisher · View at Google Scholar · View at PubMed
  54. J. E. A. Wells, R. J. Hurlbert, M. G. Fehlings, and V. W. Yong, “Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice,” Brain, vol. 126, no. 7, 1628 pages, 2003. View at Publisher · View at Google Scholar · View at PubMed
  55. A. R. Blight, “Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury,” Central Nervous System Trauma, vol. 2, no. 4, 299 pages, 1985. View at Google Scholar
  56. R. F. Gledhill, B. M. Harrison, and W. I. McDonald, “Demyelination and remyelination after acute spinal cord compression,” Experimental Neurology, vol. 38, no. 3, 472 pages, 1973. View at Publisher · View at Google Scholar
  57. M. O. Totoiu and H. S. Keirstead, “Spinal cord injury is accompanied by chronic progressive demyelination,” Journal of Comparative Neurology, vol. 486, no. 4, 373 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  58. S. D. Grossman, L. J. Rosenberg, and J. R. Wrathall, “Temporal—spatial pattern of acute neuronal and glial loss after spinal cord contusion,” Experimental Neurology, vol. 168, no. 2, 273 pages, 2001. View at Publisher · View at Google Scholar · View at PubMed
  59. M. J. Crowe, J. C. Bresnahan, S. L. Shuman, J. N. Masters, and M. S. Beattie, “Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys,” Nature Medicine, vol. 3, no. 1, 73 pages, 1997, erratum in Nature Medicine, vol. 3, no. 2, p. 240, 1997. View at Publisher · View at Google Scholar
  60. S. Casha, W. R. Yu, and M. G. Fehlings, “Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat,” Neuroscience, vol. 103, no. 1, 203 pages, 2001. View at Publisher · View at Google Scholar
  61. H. P. Raikwar, G. Muthian, J. Rajasingh, C. Johnson, and J. J. Bright, “PPARγ antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis,” Journal of Neuroimmunology, vol. 167, no. 1-2, 99 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  62. C. B. Duvanel, P. Honegger, H. Pershadsingh, D. Feinstein, and J.-M. Matthieu, “Inhibition of glial cell proinflammatory activities by peroxisome proliferator-activated receptor γ agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro,” Journal of Neuroscience Research, vol. 71, no. 2, 246 pages, 2003. View at Publisher · View at Google Scholar · View at PubMed
  63. A. R. Blight and V. Decrescito, “Morphometric analysis of experimental spinal cord injury in the cat: the relation of injury intensity to survival of myelinated axons,” Neuroscience, vol. 19, no. 1, 321 pages, 1986. View at Publisher · View at Google Scholar
  64. T. Shimazu, I. Inoue, N. Araki et al., “A peroxisome proliferator-activated receptor-γ agonist reduces infarct size in transient but not in permanent ischemia,” Stroke, vol. 36, no. 2, 353 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  65. M. T. Heneka, M. Sastre, L. Dumitrescu-Ozimek et al., “Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice,” Brain, vol. 128, no. 6, 1442 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  66. M. Sastre, I. Dewachter, S. Rossner et al., “Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPARγ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 2, 443 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  67. J. J. Bright, C. Natarajan, G. Muthian, Y. Barak, and R. M. Evans, “Peroxisome proliferator-activated receptor-γ-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis,” Journal of Immunology, vol. 71, no. 11, 5743 pages, 2003. View at Google Scholar